IL6 and delirium: An exploratory multivariate logistic regression analysis, adjusting for patient age, secondary infection, and all discrepant findings between non-survivors and survivors—days on ECMO, fatal ICH, anti-IL-6 treatment, and RV dysfunction—indicated no association between the proportion of delirium-positive days and mortality (p = 0.13).